For US Health Care Professionals

Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed) logo

Pertussis Prevention Starts Here


Each visit is a new opportunity to help protect your patients against pertussis with Adacel.1

Nurse in blue scrubs with stethoscope

Adacel is indicated for active booster immunization against tetanus, diphtheria, and pertussis. Adacel is approved for use in individuals 10 through 64 years of age.

Routine Immunization Begins with Your Adacel Recommendation

Help eligible patients stay up to date with their pertussis protection.1

Meaningful Milestones


Icon of syringe

The first dose of Adacel is administered at least 5 years after the last dose of DTaPa or Tdb.1

icon of calendar

Adacel is approved for a repeat vaccination as soon as 8 years after the initial Tdapc dose.1

Icon of bandaid

Adacel for tetanus-prone wound management may be administered as early as 5 years after a previous dose of tetanus toxoid-containing vaccine.1


After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

CONFIDENTLY HELP PRIORITIZE PERTUSSIS PREVENTION TODAY


  • More than 180 million doses of Adacel have been distributed since licensure in 20052
  • Adacel is approved for use in persons 10 through 64 years of age1
  • Adacel is available in prefilled syringes and vials made without natural rubber latex1

With Adacel, you can helpmake a difference in pertussis prevention

IMPORTANT SAFETY INFORMATION

Adacel is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any other tetanus toxoid‐, diphtheria toxoid‐, or pertussis antigen‐containing vaccine, or to any component of Adacel; or encephalopathy within 7 days after a previous dose of a pertussis antigen‐containing vaccine with no other identifiable cause.

If Guillain‐Barré syndrome or brachial neuritis has occurred within 6 weeks following previous vaccination with a tetanus toxoid‐containing vaccine or if progressive or unstable neurologic disorders exist, the decision to give Adacel should be based on careful consideration of the potential benefits and risks.

Persons who experienced an Arthus‐type hypersensitivity reaction following a prior dose of tetanus toxoid‐containing vaccine should not receive Adacel unless at least 10 years have elapsed since the last dose of tetanus toxoid‐containing vaccine.

Syncope can occur in association with administration of injectable vaccines, including Adacel. Procedures should be in place to prevent falling injury and manage syncopal reactions.

After the first and second dose of Adacel, the most frequently reported solicited reactions were pain, swelling, and erythema at the injection site; headache, body ache or muscle weakness, tiredness, myalgia, and malaise.

Other adverse reactions may occur. Vaccination with Adacel may not protect all individuals.

Please click to see full Prescribing Information.